Biaxin
NDC 54868-3820
Product Information
Biaxin is a NDA-approved product labeled by Physicians Total Care, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a yellow product. This product entry covers the primary NDC 54868-3820 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
KT
Code Structure Chart
Product Details
What is NDC 54868-3820?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CLARITHROMYCIN (UNII: H1250JIK0A)
- CLARITHROMYCIN (UNII: H1250JIK0A) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HYDROXYPROPYL CELLULOSE (UNII: RFW2ET671P)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)
- FD&C BLUE NO. 1 (UNII: H3R47K3TBD)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- POVIDONE (UNII: FZ989GH94E)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- SORBIC ACID (UNII: X045WJ989B)
- SORBITAN MONOOLEATE (UNII: 06XEA2VD56)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- VANILLIN (UNII: CHI530446X)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 197516 - clarithromycin 250 MG Oral Tablet
- RxCUI: 197517 - clarithromycin 500 MG Oral Tablet
- RxCUI: 205857 - clarithromycin 25 MG/ML Oral Suspension [Biaxin]
- RxCUI: 205857 - Biaxin 125 MG per 5 ML Granules for Oral Suspension
- RxCUI: 205857 - Biaxin 25 MG/ML Oral Suspension
* Please review the full disclaimer at the bottom of this page.